Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
, 122 (13-14), 413-22

Advantages of Moxifloxacin and Levofloxacin-based Triple Therapy for Second-Line Treatments of Persistent Helicobacter Pylori Infection: A Meta Analysis

Affiliations
Meta-Analysis

Advantages of Moxifloxacin and Levofloxacin-based Triple Therapy for Second-Line Treatments of Persistent Helicobacter Pylori Infection: A Meta Analysis

Yuqin Li et al. Wien Klin Wochenschr.

Abstract

Objective: The main aim of this meta-analysis was to compare the efficacy and safety of clarithromycin and second-generation fluoroquinolone-based triple therapy vs. bismuth-based quadruple therapy for the treatment of persistent Helicobacter pylori infection.

Methods: A systematic literature search was conducted for articles and abstracts from 1981 to March 2009 using Medline, PubMed, EMBase, Google Scholar and CNKI (Chinese), Wanfang (Chinese) digital database and recent Digestive Disease Week, United European Gastroenterology Week, and European Helicobacter Study Group conferences were also performed. Boolean operators (NOT, AND, OR) were used in succession to narrow and widen the search. Sixteen articles and four abstracts met the inclusion criteria, and were included in the meta-analysis by using Review Manager 4.2.8.

Results: The eradication rates demonstrated that clarithromycin-based triple therapy is inferior to bismuth-based quadruple therapy (OR = 0.53, 95% CI: 0.35-0.80, P = 0.002). Thirteen RCTs compared levofloxacin-based triple therapy vs. bismuth-based quadruple therapy, the eradication rates of the two regimens were shown to have no significant difference (OR = 1.43, 95% CI: 0.82-2.51, P = 0.21). But the eradication rates demonstrated superiority of the 10-day levofloxacin-based triple therapy over 7-day bismuth-based quadruple therapy (OR = 4.79, 95% CI: 2.95-7.79, P < 0.00001). Levofloxacin-based triple therapy was better tolerated than bismuth-based quadruple therapy with lower rates of side effects (OR = 0.41, 95% CI: 0.27-0.61, P < 0.0001), and lower rates of discontinuation of therapy due to adverse events (OR = 0.13, 95% CI: 0.06-0.33, P < 0.0001). Furthermore, our meta-analysis suggested that the eradication rates of the moxifloxacin-based triple therapy has a slight superiority to bismuth-based quadruple therapy, but there was no significant difference between them.

Conclusion: Second-generation fluoroquinolone-based triple therapy can be suggested as the regimen of choice for rescue therapy in the eradication of persistent H. pylori infection especially 10-day levofloxacin-based triple therapy.

Similar articles

See all similar articles

Cited by 21 PubMed Central articles

See all "Cited by" articles

References

    1. Aliment Pharmacol Ther. 2003 Feb 15;17(4):553-60 - PubMed
    1. Gut. 2007 Jun;56(6):772-81 - PubMed
    1. Wien Klin Wochenschr. 2009;121(1-2):47-52 - PubMed
    1. Aliment Pharmacol Ther. 2000 Jan;14(1):85-9 - PubMed
    1. Korean J Gastroenterol. 2008 May;51(5):285-90 - PubMed

Publication types

MeSH terms

Feedback